Decisions 14th July 2015


At the meeting that took place on 14th July, the following decisions were agreed.

New Drug Requests

Approved

Palonsetron (TLS Red)

  • Approved for inclusion onto the formulary for adults who are being treated for Hodgkin’s lymphoma.  NBT only.

Tocilizumab (subcutaneous) (TLS Red)

  • The subcutaneous preparation was approved for inclusion onto the formulary for moderate to severe rheumatoid arthritis in accordance with NICE TA 247

Brinzolamide & Brimonidine (Simbrinza) (TLS Blue)

  • Approved for inclusion onto the formulary for glaucoma patients in whom compliance is an issue.
     

Shared Care Protocols/TLS Change in Status

Rifaximin

  • The JFG approved the SCP for amber 3 months. 

Hydroxycarbamide

  • The JFG approved the updated SCP. 

Dabigatran

  • The JFG approved the SCP for the treatment and prevention of DVT/PE.

Apixaban

    • The JFG approved the SCP for the treatment and prevention of DVT/PE.

Rivaroxaban

  • The JFG approved the SCP for ACS.

 

Last updated by: Tash Mogford on 18-07-2017 11:10